|
|
|
|
||
Strong Buy
A BRIEF SUMMARY OF NNVC !From IH board : In January 2010, NNVC announced that TheraCour selling had ended and all planned funds were raised using only 1.6 of the 1.8 million shares sold off for the purpose of expanding the lab facility in order to increase production for expanded animal testing on at least four fronts: HIV, HSV, Influenza, and EKC/Eye Herpes. [I wrote this all in one breath] In February, the company announced an agreement with Berkeley and Dr. Eva Harris to test nanoviricides against Dengue. Dr. Harris is the leading researcher in Dengue and Dengue antivirals. We are awaiting initial results of that testing. In early March the company filed an S-3 for the creation of a "shelf-registration," an instrument that uses pre-registered but in this case undefined equities in order to raise up to $40 million. The advantage is that the cost of financing is significantly lowered. The S-3 filing created a quiet period, effectively a PR blackout where the release of most types of information and company news is prohibited. During that same period a series of amended 10-K annual reports have been filed in preparation for the SEC declaration of "effective" regarding the shelf registration. Some have even speculated that the 10-K/As also intend to meet new reporting demands of whatever exchange to which NNVC will up-list. There is also speculation as the SP approached and went above $2 that Dr. Seymour's intention to up-list could become a reality. There was confirmation on this board that AMEX would require 10 consecutive days of closing above $2 to affect an up-list. As of this moment, there are only 4 more days left for the 10 day period. During this entire time, and beginning last November, Agora Financial and analyst Patrick Cox have published in their expensive stock newsletter a series of articles that included NNVC as a strong buy recommendation. In the first article, NNVC was only included in a basket of recommended stocks. More recently NNVC was featured in articles in the newsletter with the most recent being last Tuesday. These newsletters seem to have added significantly to interest in the company. Finally, John Mauldin of Investor's Insight was reported by several chat board participants as having recommended NNVC during a segment on FOX Business Channel. We are now waiting for 1) the shelf registration to be declared effective by the SEC, 2) the quiet period to end, 3) up-dates on Dengue, HIV, HSV, Eye Herpes among other in vitro and in vivo testing, 4) any other and every other material event that can't be reported during the quiet period. |
return to message board, top of board |